ABSTRACT Introduction: Intravenous Immunoglobulin preparations have long been used as
an effective therapeutic approach to patients with predominant antibody deficiencies. The …

Objective: The expansion of immunoglobulin replacement to multiple disease entities marks
a decade-long advancement in immune therapy. Parallel to its extension, the characteristics …

Both intravenous and subcutaneous immunoglobulins are therapeutic modalities approved
in various conditions, including primary and secondary immune deficiencies and …

Immunoglobulin therapy has not only served as a lifesaving approach for the prevention and
treatment of infections in primary and secondary immunodeficiency diseases, but has also …

The processes of isolation and sterilization of intravenous gamma globulin (IVIG) affect the
end product characteristics and, therefore, its tolerability. Different products have different …

This is a comment on" Clinical, immunological, and molecular analysis in a large cohort of
patients with X-linked agammaglobulinemia: an Italian multicenter study." Clin Immunol …

Although US immune globulin intravenous (human)(IGIV) products have been regarded as
safe, it is important to recognize that many of the controlled clinical studies of IGIVs have …

The first therapeutic indication, and still currently the most applied of gamma globulin, is the
one which uses its substitutive capacity in patients with antibodies deficiencies. Its …

The development of intravenous IgG (IVIG) formulations in the 1970s enabled expanded use
for treating primary antibody deficiency syndromes and autoimmune conditions. Recent …

Immunoglobulins (IgG) as replacement therapy in primary antibody deficiencies can be
given as intramuscular injections, or as intravenous or subcutaneous infusions. Our aims …